Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 12
2021 9
2022 8
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. NPJ Breast Cancer. 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. NPJ Breast Cancer. 2023. PMID: 37069173 Free PMC article.
Current Understanding of Urachal Adenocarcinoma and Management Strategy.
Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, Mennitto R, de Braud FGM, Verzoni E, Procopio G. Claps M, et al. Among authors: zattarin e. Curr Oncol Rep. 2020 Jan 27;22(1):9. doi: 10.1007/s11912-020-0878-z. Curr Oncol Rep. 2020. PMID: 31989430 Review.
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.
Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, Sposetti C, Provenzano L, Azzollini J, Vingiani A, Ferraris C, Martelli G, Manoukian S, Pruneri G, de Braud F, Vernieri C. Zattarin E, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104109. doi: 10.1016/j.critrevonc.2023.104109. Epub 2023 Aug 27. Crit Rev Oncol Hematol. 2023. PMID: 37643668 Review.
The emerging role of PARP inhibitors in prostate cancer.
Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G. Stellato M, et al. Among authors: zattarin e. Expert Rev Anticancer Ther. 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6. Expert Rev Anticancer Ther. 2020. PMID: 32758032 Review.
37 results